Publication Name	World Journal of Gastroenterology
Manuscript ID	61946
Country	Croatia

Received	2020-12-23 16:24
Peer-Review Started	2020-12-24 13:19
To Make the First Decision
Return for Revision	2021-02-11 03:30
Revised	2021-02-14 08:14
Second Decision	2021-03-17 10:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-17 15:23
Articles in Press	2021-03-17 15:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-02 10:14
Publish the Manuscript Online	2021-04-09 09:07

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Opinion Review
Article Title	How far along are we in revealing the connection between metformin and colorectal cancer?
Manuscript Source	Invited Manuscript
All Author List	Maja Cigrovski Berkovic, Danko Mikulic, Ines Bilic-Curcic and Anna Mrzljak
Funding Agency and Grant Number
Corresponding Author	Anna Mrzljak, FEBG, MD, PhD, Associate Professor, Department of Medicine, Merkur University Hospital, School of Medicine, Zajčeva 19, Zagreb 10000, Croatia. anna.mrzljak@gmail.com
Key Words	Metformin; Type 2 diabetes mellitus; Colorectal cancer; Chemoprevention; Recurrence-free survival; Surgery
Core Tip	Metformin is one of the oldest oral antidiabetic agents used to treat type 2 diabetes mellitus. While there is substantial evidence that metformin may have a chemopreventive role in colorectal cancer (CRC) development, the data on the possible effects of metformin after surgery and other CRC treatment is much less conclusive.
Publish Date	2021-04-09 09:07
Citation	Cigrovski Berkovic M, Mikulic D, Bilic-Curcic I, Mrzljak A. How far along are we in revealing the connection between metformin and colorectal cancer? World J Gastroenterol 2021; 27(14): 1362-1368
URL	https://www.wjgnet.com/1007-9327/full/v27/i14/1362.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i14.1362

Full Article (PDF)	WJG-27-1362.pdf
Full Article (Word)	WJG-27-1362.docx
Manuscript File	61946_Auto_Edited_LM.docx
Answering Reviewers	61946-Answering reviewers.pdf
Audio Core Tip	61946-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	61946-Conflict-of-interest statement.pdf
Copyright License Agreement	61946-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	61946-Language certificate.pdf
Peer-review Report	61946-Peer-review(s).pdf
Scientific Misconduct Check	61946-Bing-Wang JL-1.jpg
Scientific Misconduct Check	61946-Bing-Fan JR-2.png
Scientific Misconduct Check	61946-Scientific misconduct check.pdf
Scientific Editor Work List	61946-Scientific editor work list.pdf